— Latest update: July 2022 —
With the world’s highest proportion of the elderly (nearly 30% in 2020), the number of patients with cancer and other diseases is expected to increase in Japan. It is the third largest pharmaceutical market in the world, and the biologically active substances (biopharmaceuticals) are considered to be the driving force behind innovation in this industry. In 2021, the Japanese biopharmaceutical market value was estimated at 2,1 trillion yen. Even though the pharmaceutical market growth is projected to be negative, the biopharmaceutical sector is expected to grow.
EU-Japan Centre, The Biopharmaceuticals sector in Japan, 2019
EU-Japan Centre, Latest trends in biotechnology research in Japan, 2021
JETRO, Life Science Report, 2022
International Trade Administration, Japan-Pharmaceuticals, 2022
> For more information about the Japanese pharmaceutical market, laws, and regulations, click here
Which opportunities does the Biopharmaceutical market in Japan offer to EU companies?Among Biotechnology, the field of biopharmaceuticals is a core sector in terms of market size and growth potential
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
Hundreds of web pages with up-to-date information on Japan, more than 400 market reports and recorded webinars available as well as a lot of detailed information on Japanese business culture.